Market Overview

UPDATE: Jefferies Reiterates Buy Rating, Lowers PT on Myriad Genetics on New Medicare Code Values

Related MYGN
Myriad RBM DiscoveryMAP Technology Identifies Novel Biomarkers That May Predict Increased Risk of Cardiovascular Events in Patients With Diabetes
Crescendo Bioscience Vectra DA Data to be Presented at American College of Rheumatology 2015 Annual Meeting

In a report published Monday, Jefferies reiterated its Buy rating on Myriad Genetics (NASDAQ: MYGN), but lowered its price target from $33.00 to $31.00.

Jefferies noted, “Noridian, MYGN's designated Medicare contractor, released the highly anticipated new molecular pathology reimbursement codes for CY13. The new codes suggest an 8% decrease and a 14% increase for MYGN's BRACAnalysis and COLARIS tests, respectively, relative to current commercial reimbursement rates. We are trimming our FY14 EPS forecast to $1.60 (from $1.65) on the disclosure. Our PT moves to $31 (from $33) on lower cash flow forecasts.”

Myriad Genetics closed on Friday at $25.46.

Latest Ratings for MYGN

Sep 2015Stephens & Co.MaintainsOverweight
Sep 2015JefferiesMaintainsHold
Sep 2015Piper JaffrayMaintainsOverweight

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (MYGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters